1. Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years
- Author
-
Koki Sato, Takamasa Ohki, Nobuo Toda, Mayuko Kondo, Kyohei Tsuchiya, and Kazumi Tagawa
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Percutaneous ,Multivariate analysis ,Radiofrequency ablation ,Locoregional therapy ,Gastroenterology ,law.invention ,Therapy naive ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,Propensity score matching ,medicine ,In patient ,Alanine aminotransferase ,Hepatocellular carcinoma (HCC) ,lcsh:RC799-869 ,Prothrombin time ,Hepatology ,medicine.diagnostic_test ,business.industry ,Radiofrequency ablation (RFA) ,medicine.disease ,Elderly patients ,030104 developmental biology ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,lcsh:Diseases of the digestive system. Gastroenterology ,business - Abstract
Background: Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80 years. This study aimed to determine the efficacy and safety of RFA for HCC in patients aged ≥80 years. Methods: A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled. They were categorized into the ≥80-year-old group and the control group (aged
- Published
- 2020